Ribo Newsroom
-
Ribo Appoints CMO and CBO to Empower Global R&D and PartnershipsRibo Appoints CMO and CBO to Empower Global R&D and PartnershipsMarch 26, 2026 -
Ribo expands beyond the liver with RiboPepSTAR? – enabling targeted siRNA delivery to multiple organsRibo expands beyond the liver with RiboPepSTAR? – enabling targeted siRNA delivery to multiple organsMarch 20, 2026 -
Ribo to present ex-hepatic delivery data at RNA Leaders Europe ConferenceRibo has been invited to give a speech at the RNA Leaders Europe Conference in Vienna, Austria on March 19th, one of the top oligonucleotide conferences.March 17, 2026 -
Ribo's PCSK9-targeting siRNA drug RBD7022 is about to launch Phase III clinical trials in China.Ribo's PCSK9-targeting siRNA drug RBD7022 is about to launch Phase III clinical trials in China.March 2, 2026 -
Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASHRibo entered into an exclusive worldwide license agreement with Madrigal for six pre-clinical siRNA programs for the treatment of MASH.February 11, 2026 -
Recent advances in factor XI (FXI) inhibition are reshaping the landscape of anticoagulation therapyRecent advances in factor XI (FXI) inhibition are reshaping the landscape of anticoagulation therapyFebruary 9, 2026